Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The main objective of the study is to evaluate the efficacy and safety of maintenance therapy
with hypomethylating agent and Venetoclax to improve leukemia free survival for high-risk
myeloid malignancies after allogeneic hematopoietic stem cell transplantation .
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine